Literature DB >> 30426235

Residual symptoms and disease burden among patients with psoriatic arthritis: is a new disease activity index required?

Gamze Kilic1, Erkan Kilic2, Kemal Nas3, Ayhan Kamanlı3, İbrahim Tekeoglu3.   

Abstract

The aim of this study was to investigate residual symptoms or disease burden among patients with psoriatic arthritis (PsA) in remission or low disease activity (LDA) according to different outcome measures. A total of 126 patients with PsA were included and the following variables were assessed: Tender joint count (TJC), swollen joint count (SJC), patient's global assessment, physician's global assessment, pain, extra-articular manifestations, Psoriasis Area and Severity Index, Health Assessment Questionnaire, fatigue, Short Form-36, psoriatic quality of life, Hospital Anxiety and Depression Scale and C-reactive protein (CRP). Disease activity was measured using three different outcome measures including minimal disease activity (MDA), disease activity score for 28 joints (DAS28-CRP) and disease activity in psoriatic arthritis (DAPSA). The number (%) of patients who achieved remission or LDA was 9(14.1), 34(27.0) and 67(53.2) according to MDA, DAPSA and DAS28-CRP criteria, respectively, under usual care. SJC > 1 was seen in 3(8.8%) and 13(19.4%) of patients in remission or LDA as defined by the DAPSA and DAS28-CRP respectively. TJC > 1 was found at least 32.4% of patients with PsA in remission or LDA by any definition. 22.2-49.3% of patients with PsA in remission or LDA still suffered from clinically important fatigue. No patients in MDA had a substantial functional impairment while 2.9-19.4% of patients fulfilling remission or LDA according to the DAPSA and DAS28-CRP experienced functional disability. At least 22.2% of patients with PsA in remission or LDA by any description had higher risk for depression, and at least 11.1% for anxiety. Despite patients with PsA in remission or LDA by various definition, they may continue to experience pain, tender or swollen joints, fatigue, physiologic distress as well as functional impairment suggesting that there is a significant unmet need with regard to definition of remission or LDA in PsA.

Entities:  

Keywords:  Disease activity; Disease burden; Minimal disease activity; Psoriatic arthritis; Remission

Mesh:

Substances:

Year:  2018        PMID: 30426235     DOI: 10.1007/s00296-018-4201-3

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  50 in total

1.  Health-related quality of life of patients with psoriatic arthritis: a comparison with patients with rheumatoid arthritis.

Authors:  J A Husted; D D Gladman; V T Farewell; R J Cook
Journal:  Arthritis Rheum       Date:  2001-04

2.  Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment.

Authors:  L C Coates; J Fransen; P S Helliwell
Journal:  Ann Rheum Dis       Date:  2010-01       Impact factor: 19.103

3.  Application of the DAREA/DAPSA score for assessment of disease activity in psoriatic arthritis.

Authors:  Monika Schoels; Daniel Aletaha; Julia Funovits; Arthur Kavanaugh; Daniel Baker; Josef S Smolen
Journal:  Ann Rheum Dis       Date:  2010-06-04       Impact factor: 19.103

4.  [Prevalence of symptoms of anxiety and depression in patients with psoriatic arthritis attending rheumatology clinics].

Authors:  Mercedes Freire; Jesús Rodríguez; Ingrid Möller; Antonio Valcárcel; Carmelo Tornero; Gemma Díaz; Yolanda Armendáriz; Silvia Paredes
Journal:  Reumatol Clin       Date:  2010-06-15

5.  Severe psoriasis--oral therapy with a new retinoid.

Authors:  T Fredriksson; U Pettersson
Journal:  Dermatologica       Date:  1978

6.  Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis.

Authors:  Laura C Coates; Arthur Kavanaugh; Philip J Mease; Enrique R Soriano; Maria Laura Acosta-Felquer; April W Armstrong; Wilson Bautista-Molano; Wolf-Henning Boehncke; Willemina Campbell; Alberto Cauli; Luis R Espinoza; Oliver FitzGerald; Dafna D Gladman; Alice Gottlieb; Philip S Helliwell; M Elaine Husni; Thorvardur J Love; Ennio Lubrano; Neil McHugh; Peter Nash; Alexis Ogdie; Ana-Maria Orbai; Andrew Parkinson; Denis O'Sullivan; Cheryl F Rosen; Sergio Schwartzman; Evan L Siegel; Sergio Toloza; William Tuong; Christopher T Ritchlin
Journal:  Arthritis Rheumatol       Date:  2016-03-23       Impact factor: 10.995

7.  Radiographic Progression of Patients With Psoriatic Arthritis Who Achieve Minimal Disease Activity in Response to Golimumab Therapy: Results Through 5 Years of a Randomized, Placebo-Controlled Study.

Authors:  Arthur Kavanaugh; Désirée van der Heijde; Anna Beutler; Dafna Gladman; Philip Mease; Gerald G Krueger; Iain B McInnes; Philip Helliwell; Laura C Coates; Stephen Xu
Journal:  Arthritis Care Res (Hoboken)       Date:  2016-02       Impact factor: 4.794

8.  Management of Psoriatic Arthritis: Turkish League Against Rheumatism (TLAR) Expert Opinions.

Authors:  Kemal Nas; Erkan Kiliç; Remzi Çevik; Hatice Bodur; Şebnem Ataman; Figen Ayhan; Özgür Akgül; Ayşen Akinci; Zuhal Altay; Erhan Çapkın; Abdullah Zübeyir Dağli; Tuncay Duruöz; Gülcan Gürer; Feride Göğüş; Yeşim Garip; Cahit Kaçar; Ayhan Kamanli; Ece Kaptanoğlu; Taciser Kaya; Hilal Kocabaş; Erhan Ali Özdemirel; Sumru Özel; İlhan Sezer; İsmihan Sunar; Gürkan Yilmaz
Journal:  Arch Rheumatol       Date:  2018-05-21       Impact factor: 1.472

9.  Measurement of patient outcome in arthritis.

Authors:  J F Fries; P Spitz; R G Kraines; H R Holman
Journal:  Arthritis Rheum       Date:  1980-02

10.  Residual disease activity and treatment adjustments in psoriatic arthritis in current clinical practice.

Authors:  Leonieke J J van Mens; Marleen G H van de Sande; Inka A Fluri; Sadaf Atiqi; Arno W R van Kuijk; Dominique L P Baeten
Journal:  Arthritis Res Ther       Date:  2017-10-10       Impact factor: 5.156

View more
  4 in total

Review 1.  Residual Disease Associated with Suboptimal Treatment Response in Patients with Psoriatic Arthritis: A Systematic Review of Real-World Evidence.

Authors:  Laura C Coates; Maarten de Wit; Amy Buchanan-Hughes; Maartje Smulders; Anna Sheahan; Alexis R Ogdie
Journal:  Rheumatol Ther       Date:  2022-04-12

2.  Exploring cannabis use and perspectives among psoriatic disease patients.

Authors:  Jackie Tsang; Orli Silverberg; Rohan Machhar; Remy Pollock; Daniel Pereira; Mitchell Sutton; Dafna D Gladman; Cheryl F Rosen
Journal:  Clin Rheumatol       Date:  2022-01-20       Impact factor: 3.650

3.  Residual Disease in Patients with Axial Spondyloarthritis: A Post-Hoc Analysis of the QUASAR Study.

Authors:  Salvatore D'Angelo; Carlo Salvarani; Francesca Marando; Giuliana Gualberti; Lucia Novelli; Giacomo Curradi; Giovanni Tripepi; Annalisa Pitino; Roberta Ramonda; Antonio Marchesoni
Journal:  J Clin Med       Date:  2022-06-20       Impact factor: 4.964

4.  Identifying and Quantifying the Role of Inflammation in Pain Reduction for Patients With Psoriatic Arthritis Treated With Tofacitinib: A Mediation Analysis.

Authors:  Kurt de Vlam; Philip J Mease; Andrew G Bushmakin; Roy Fleischmann; Alexis Ogdie; Valderilio F Azevedo; Joseph F Merola; John Woolcott; Joseph C Cappelleri; Lara Fallon; Peter C Taylor
Journal:  Rheumatol Ther       Date:  2022-09-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.